Comparative Effectiveness of Positive Airway Pressure Therapy, Dental Device, and Atomoxetine-Oxybutynin for Sleep Apnea: the ADAPT-OSA Study

Researchers want to identify which treatments for obstructive sleep apnea (OSA) work best and are easiest for patients to use consistently. The ADAPT-OSA trial is open to adults who have recently been diagnosed with obstructive sleep apnea (OSA) and live near one of the study sites in Tucson, AZ; Baltimore, MD; Miami, FL; or Palo Alto, CA. Eligible participants will be randomly assigned one of three OSA treatments: traditional PAP therapy, a dental device, or a combination of two FDA-approved medications (atomoxetine and oxybutynin) that are currently approved for other conditions. The study will help cover the cost of PAP or dental device therapy and will provide medications at no cost to participants assigned to that treatment. Over the course of one year, participants will attend two in-person visits and take part in four phone check-ins to complete surveys, report any side effects, and discuss how well they are following their assigned treatment.